首页> 美国卫生研究院文献>ACS Central Science >The Proteasome in Modern Drug Discovery: Second Lifeof a Highly Valuable Drug Target
【2h】

The Proteasome in Modern Drug Discovery: Second Lifeof a Highly Valuable Drug Target

机译:现代药物发现中的蛋白酶体:第二生命高价值药物目标的确定

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

As the central figure of the cellular protein degradation machinery, the proteasome is critical for cell survival. Having been extensively targeted for inhibition, the constitutive proteasome has proven its role as a highly valuable drug target. However, recent advances in the protein homeostasis field suggest that additional chapters can be added to this successful story. For example, selective immunoproteasome inhibition promises high clinical efficacy for autoimmune disorders and inflammation, and proteasome inhibitors might serve as novel therapeutics for malaria or other microorganisms. Furthermore, utilizing the destructive force of the proteasome for selective degradation of essential drivers of human disorders has opened up a new and exciting area of drug discovery. Thus, the field of proteasome drug discovery still holds exciting questions to be answered and does not simply end with inhibiting the constitutive proteasome.
机译:作为细胞蛋白质降解机制的核心人物,蛋白酶体对于细胞存活至关重要。组成型蛋白酶体已被广泛地抑制,已证明其作为高度有价值的药物靶标的作用。但是,蛋白质稳态领域的最新进展表明,可以将其他章节添加到这个成功的故事中。例如,选择性的免疫蛋白酶体抑制有望对自身免疫性疾病和炎症具有很高的临床疗效,并且蛋白酶体抑制剂可以作为疟疾或其他微生物的新型治疗剂。此外,利用蛋白酶体的破坏力选择性降解人类疾病的基本驱动因素,开辟了新的令人兴奋的药物发现领域。因此,蛋白酶体药物发现领域仍然存在令人兴奋的问题要回答,而不仅仅是以抑制组成型蛋白酶体结尾。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号